What is the evidence?
|
|
- Godfrey Cory Jennings
- 6 years ago
- Views:
Transcription
1 Katie Snell, MSN, AGNP-C NP CARE Clinic, University of Colorado Hospital, Dept of Oncology EBP is the integration of clinical expertise, patient values, and the best research evidence into the decision making process for patient care. Clinical expertise refers to the clinician s cumulated experience, education and clinical skills. The patient brings to the encounter his or her own personal preferences and unique concerns, expectations, and values. The best research evidence is usually found in clinically relevant research that has been conducted using sound methodology. (Sackett D, 2002) Experiential knowledge Reflective practice Experience and opinions of Others Carper- 4 ways of knowing in nursing- Empirics, ethics, esthetics, personal Intuition Unknowing EBP
2 A blend of evidence, tradition and experiential practice How do you know if what you practice is based on the evidence? Is there any evidence? Fear of harming patient Understanding of pathophysiology behind treatment Totally implantable device Used for long term access and therefore a frequent choice in the infusion center Lowest rate of infection when compared to other central access devices Port infections can occur due to contamination during insertion and migration of resident epidermal flora such as staphylococcus and candida (Eisenberg, 2011) Infection can occur in the portal body or within the catheter lumen (Camp-Sorrell,2009) It is often very difficult to determine the source of infection and the cause Sterile versus clean technique Sterile or aseptic technique- use of sterile gloves, mask, sterile field, disinfect skin, use sterile saline to prime sterile non coring port needle, no touch technique (Baumgartner et al, 2007) Clean procedure- non sterile gloves, clean field, disinfect skin, use prefilled saline syringe to prime sterile non coring port needle, no touch technique (Camp-Sorrell, 2009) What is the evidence? CDC Scrub port site with chlorhexidine and use sterile device 1A. Clean or sterile gloves INS standards aseptic technique when accessing port, use of mask is recommended but unresolved due to lack of research D National EB guidelines UK- Aseptic technique should be used for any procedure that breeches the body s natural defense (Loveday et al, 2014). D ONS Recommendation- Although evidence does not exist to support sterile maintenance procedures for specialty access devices (e.g. access to CSF), expert opinion and sound nursing judgment supports use of sterile technique when accessing these devices, as life-threatening infection could occur (Cope, 2011). No PEP guidelines Rinke et al, (2012)- Studies advocating sterile techniques when accessing ports are inconclusive- peds Bard access systems aseptic technique ASCO- In 2003 and 2006, the American Society of Clinical Oncology (ASCO) convened an expert panel to develop guidelines for VAD maintenance and care (including port access and deaccess) and management of complications. To date, the panel has not been able to develop guidelines based on current data. Thus, ASCO has not recommended sterile technique Schulmeister (1987) evaluated non sterile v sterile gloves for port access. 40 venous ports randomly assigned to gloved or non gloved procedure. No infection rate in either group Camp- Sorrell (2009)- Clean technique used to access ports in rural hem- onc clinic over 1 year period. Chart review showed of 62 patients, six developed port infection. However, patients had co morbidities that may have caused infection including cellulitis, infected sutures and neutropenic fevers Hemsworth et al (2007)- Non sterile gloves worn during 36 month prospective study on oncology peds unit in UK. Not exclusively port access. NO difference in infection rates
3 Cost saving- sterile technique is more expensive Time saving- sterile technique takes longer to set up Patient satisfaction? How do you really achieve a sterile field in an open infusion area? Very few randomized clinical trials- based on experience and expert consensus. Every facility is different and not based on facts (Conley, 2015) 30 second scrub is EBP, nothing else is! To date, no satisfactory studies have examined a relationship between wearing sterile gloves and prevention of infection in central lines- ritualistic not EBP (Hemsworth et al, 2007) Sterile technique during insertion has proven benefits, is this why recommendations still advocate sterile technique when accessing? (Eisenberg, 2011). Randomized clinical trials are needed Is there enough evidence to support change in practice? Change in culture We all give drugs in a particular order Why? Evidence or experience? A common misconception is that agents have been tested as part of a regimen Most commonly used sequences for multi drugs based on how it was done in clinical trials Some sequences based on pharmacology Sequencing rarely affects efficacy but can cause toxicity Affects repair of cancer cells Synergy Multi drug regimens Additive effects of individual drugs when combined Single agents have not increased cure rate Based on common sense and clinical practice- Vesicant-irritant-non vesicant Monoclonal antibody first- deal with reaction early. (Conflicting evidence in R-CHOPP) Evidence based interventions- Avastin first- more effective chemo delivery Pay your taxes first!! If platinum's given first there is 33% reduction in Taxol clearance causing increased myelosuppression
4 First agent Second agent Sequence benefit 5FU MTX Better response and survival rates Cisplatin Irinotecan Better response rate, less toxicity Cytoxan Paclitaxel Less cytopenias Taxotere Vinorelbine Decreased neutropenia Taxotere Topotecan Decreased neutropenia, reverse sequence causes a 50% reduction in taxotere clearance Doxorubicin Paclitaxel Reversed sequence leads to decreased clearance of doxorubicin leading to myelosuppression and mucositis Doxorubicin Docetaxel Less grade 4 neutropenia Epirubicin Paclitaxel Reversed sequence leads to decreased clearance of epirubicin leading to myelosuppression and mucositis Fludarabine Cytarabine Enhances efficacy Gemcitabine Cisplatin Increases effect of Cisplatin and lessens neutropenia, less toxic Ifosfamide Docetaxel Less myelosuppression Irinotecan 5FU Additive efficacy, less diarrhea and neutropenia Leucovorin 5FU Stabilizes thymidylate synthase increase 5FU cytotoxicity and efficacy MTX Leucovorin Leucovorin rescues cells after MTX administered to reduce toxicity. If leucovorin given first, it decreases efficacy of MTX What infusions do you titrate? Is this evidence based practice? Why do you titrate? Should you titrate every infusion? Paclitaxel Cisplatin Less neutropenia Paclitaxel Gemcitabine Synergy, less risk of hepatotoxicity Pemetrexed Gemcitabine Most efficacious, less toxic Topotecan Carboplatin Less risk of neutropenia and thrombocytopenia Topotecan Cisplatin Less risk of neutropenia and thrombocytopenia Definition: a disorder characterized by adverse reaction to the infusion of pharmacological or biological substances Taxanes- 44% minor reactions, 1.5-3% major anaphylaxis. 95% of all taxane reactions are with dose 1 and are rapid onset Monoclonal antibodies-77% of patients react to dose 1, but rarely grade 3-4 reaction Platinums- 27% incidence in patients receiving 7 or more infusions, 1.5-3% in less than 7 3 Types: Hypersensitivity- IgE antibodies produced in response to foreign body. Bind to receptors on mast cells and basophils With subsequent infusions the IgE antibodies react to known antigens causing histamine release Platinums Anaphylactoid Immediate effect Directly affects immune cells causing histamine release Occurs with first or second infusion, progresses rapidly Taxanes Cytokine release Produced by T cells during inflammatory response to non human part of monoclonal antibody Cytokines act as messengers and coordinate immune and inflammatory response Monoclonal antibodies
5 Know what you are giving and the risk of reaction Know what kind of reaction you may see Thorough patient history- prior reactions to current meds and any others. Allergy history, asthma, atopic history, iodine, shellfish allergy, female. High lymphocyte count (>25,000) Test dosing is unreliable and not based on evidence Standard pre medication regimen Patient education Anaphylactoid type reaction Immediate onset Reaction to cremaphor (castor oil and ethanol) There is no evidence to support or refute titration Common sense- if someone may react, go slow so they get less drug. Titrating past dose 2 is not necessary Dexamethasone PO 12 and 6 hours prior to treatment is superior to IV dexamethasone 30 min prior Gently invert Taxol bag prior to hanging Pre medications Decadron- stabilizes mast cell membranes and prevents degranulation H1 blockers- Blocks binding of histamine to H1 receptors on target cells H2 blockers- stops cells from responding to histaminereduces mucous secretion and vascular smooth muscle relaxation Tylenol- Antipyretic Reaction medications Epinephrine- drug of choice for anaphylaxis, rarely used. ROA, no contraindications H1, H2 blockers- slow onset Bronchodilators Corticosteroids- decrease duration and prevents biphasic reactions IV fluids, Dopamine Rituxan can safely be given Over 90 mins if no or Minimal reaction to dose 1 EBP- RATE trial 2012 Approved by FDA At present only approved in NHL/Follicular lymphoma. Plan for CLL and non heme conditions No CV disease, lymphocyte count less than 5000 Dose 2 onwards- 20% over 30 min, 80% over 1 hour Usually given in less volume Patient satisfaction
6 Used frequently in infusion centers for Crohns, Colitis, rheumatiod arthritis Increasingly used to treat side effects of immunotherapy Anti TNF monoclonal antibody Manufacturers recommend 2 hour titrated infusion with each dose- 20cc/hr x 5cc, 40cc/hr x 10cc, 80cc/hr x 20cc, 160cc/hr x 40cc and 250cc x remainder Studies performed in IBD and RA. No change in infusion reactions if given rapidly Protocols recommend doses 1-4 over 2 hours, 5-10 over 1 hour, then 30 mins thereafter Pre medication not universal What is your burning question?? Consider undertaking evidence based practice projects in your infusion center You have a captive audience, use them! Ask why? Review literature and stay up to date Question own practice Question MD orders and standardized protocols Use drug companies, they can provide literature Librarian, Nursing research councils
Emergency clamp should always be readily available in case of accidental catheter fracture
Note: Please see individual policies for further information. Flushing best practice: Always use a 10 diameter syringe or larger when first accessing and when flushing vascular access device (VAD) Use
More informationAppendix E: Overview of Vascular
Appendix E: Overview of Vascular 56 Peripheral Short Catheter, less than 3 inches (7.5 cm) in length; over-the-needle catheter is most common. Inserted by percutaneous venipuncture, generally into a hand
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationCENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON
CENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON Aims and Objectives To know what central venous access devices (CVAD) are. Types of CVADS used in haematology. To understand why we use them To know the complications
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationSuccessful IV Starts Revised February 2014
Successful IV Starts Revised February 2014 Why Intravenous Therapy? Used for access to the body s circulation Indications: Administer fluids, blood, medications, and nutrition Obtain laboratory specimens
More informationOverview Of Allergy Testing Methods
Overview Of Allergy Testing Methods Hector P. Rodriguez MD Columbia Presbyterian Medical Center Inhalant Allergy Mechanism Antibody (Ab( Ab): allergen-specific IgE Binds to specific receptors on mast cells
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationSARASOTA MEMORIAL HOSPITAL
SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE DATE: REVIEWED: PAGES: 03/86 7/18 1 of 13 PS1094 ISSUED FOR: Nursing RESPONSIBILITY: RN Chemo Qualified PURPOSE: To provide the RN with specific steps
More informationTo help doctors give their patients the best possible care, the American. What to Know
Patient Information Resources from ASCO What to Know ASCO s Guideline on Chemotherapy for Stage IV Non-Small Cell Lung Cancer SEPTEMBER 2011 KEY MESSAGES Chemotherapy for stage IV non-small cell lung cancer
More informationIf viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.
If viewing a printed copy of this policy, please note it could be expired. Got to www.fairview.org/fhipolicies to view current policies. Department Policy Code: D: PC-5555 Entity: Fairview Pharmacy Services
More informationIV Drug Delivery Systems used in Cancer Care
IV Drug Delivery Systems used in Cancer Care Cheri Constantino-Shor, RN, MSN, CRNI Seattle Cancer Care Alliance Nursing Staff Development Coordinator Presentation Objective Describe drug delivery devices
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationCentral Venous Access Devices and Infection
Central Venous Access Devices and Infection Dr Andrew Daley Microbiology & Infectious Diseases Women s & Children s Health Melbourne Background Types of infection! Local site infection! Blood stream infection!
More informationATI Skills Modules Checklist for Central Venous Access Devices
For faculty use only Educator s name Score Date ATI Skills Modules Checklist for Central Venous Access Devices Student s name Date Verify order Patient record Assess for procedure need Identify, gather,
More informationIV therapy. By: Susan Mberenga, RN, MSN. Copyright 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc.
IV therapy By: Susan Mberenga, RN, MSN 1 IV Therapy Types of solutions Isotonic Hypotonic Hypertonic Caution: Too rapid or excessive infusion of any IV fluid has the potential to cause serious problems
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationInfusion Coding Infusions, Pushes, Injections
Infusion Coding Infusions, Pushes, Injections Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions
More informationChapter 38- Immune System
Chapter 38- Immune System First Line of Defense: Barriers Nonspecific defenses, such as the skin and mucous membranes, are barriers to potential pathogens. In addition to being a physical barrier to pathogens,
More informationDirect Intravenous (IV) Medication Administration Procedure
Approved by: Chief Medical Officer; and Chief Operating Officer Direct Intravenous (IV) Medication Administration Procedure Corporate Policy & Procedures Manual Number: VII-B-310 Date Approved January
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationCentral Line Care and Management
Central Line Care and Management What is a Central Line/ CVAD? (central venous access device) A vascular infusion device that terminates at or close to the heart or in one of the great vessels (aorta,
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationHypersensitivity is the term used when an immune response results in exaggerated or inappropriate reactions harmful to the host.
Hypersensitivity is the term used when an immune response results in exaggerated or inappropriate reactions harmful to the host. Hypersensitivity vs. allergy Hypersensitivity reactions require a pre-sensitized
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationParenteral Nutrition in the Hospitalized Patient: which VAD, which policies? Rob Dawson DNP, MSA, APRN, ACNP-BC, VA-BC USA
Parenteral Nutrition in the Hospitalized Patient: which VAD, which policies? Rob Dawson DNP, MSA, APRN, ACNP-BC, VA-BC USA Disclosure Consultant, Vascular Access Consultants LLC: Analogic, Inc / BK Ultrasound
More informationSELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS Manufacturing specialized products in a pharmaceutical
More informationLearn Connect Succeed. JCAHPO Regional Meetings 2017
Learn Connect Succeed JCAHPO Regional Meetings 2017 Intravitreal Injection Technique Updated Recommendations from an Expert Panel Sophie J. Bakri, M.D. Professor of Ophthalmology Vitreoretinal Diseases
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationThe Impact of Healthcare Associated Infection (HCAI)
Instructions for use Save this presentation Feel free to add or delete slides as necessary, change information to suit local needs and as new guidance or evidence is published Disclaimer: Whilst the working
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationWound culture. (Sampling methods) M. Rostami MSn.ICP Rajaei Heart Center
Wound culture (Sampling methods) M. Rostami MSn.ICP Rajaei Heart Center Infection is a major impairment in delayed and nonhealing chronic wounds. Cultures of chronic wounds are not routinely performed
More informationHome Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE
UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS UMHHC-HCS: 253.054 First Approved Date: 3/2010 Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating
More informationNCCP Chemotherapy Regimen. FLOT Therapy-14 day
INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationGuidelines for the Care and Maintenance of Intravenous Access Devices in Paediatric Patients
Guidelines for the Care and Maintenance of Intravenous Access Devices in Paediatric Patients These guidelines have been adapted for local use from the Collaborative Intravenous Nursing Services regional
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationNursing Services Fall 2011
Nursing Services Fall 2011 RCW 28A.210.320 states life-threatening condition means a health condition that will put the child in danger of death during the school day. Medical Orders Staff Education Student
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationImmunologic Mechanisms of Tissue Damage. (Immuopathology)
Immunologic Mechanisms of Tissue Damage (Immuopathology) Immunopathology Exaggerated immune response may lead to different forms of tissue damage 1) An overactive immune response: produce more damage than
More informationE.N : Tubal Feeding Systems ; Closed vs. Open
E.N : Tubal Feeding Systems ; Closed vs. Open Dr:Enas Mogawer, MD Head Of Clinical Nutrition Department,AFSH Professor Of Internal Medicine Kasr El Aini Medical Consultant Of Clinical Nutrition And Obesity
More informationThe University of Toledo Medical Center and its Medical Staff
Name of Policy: Policy Number: Department: 3364-109-GEN-705 Infection Control Medical Staff Hospital Administration Approving Officer: Responsible Agent: Scope: Chair, Infection Control Committee Chief
More informationInfusion Skills Competency Checklist To be used at annual skills fair or at any other time for IV Competency
Employee Profile Infusion Skills Checklist Last Name First Name Middle Initial Employee Number Employee Discipline Check one: RN LPN Per state specific LPN Practice Acts Direct Supervisor s Name: Date
More informationFOR A HIGHER DEGREE OF CONFIDENCE
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS. > Introduction Manufacturing specialized products in a pharmaceutical manufacturing environment has a specific set of requirements
More informationIf viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.
If viewing a printed copy of this policy, please note it could be expired. Got to www.fairview.org/fhipolicies to view current policies. Department Policy Code: D: PC-5575 Entity: Fairview Pharmacy Services
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationDepartment Policy. Code: D:PC Entity: Fairview Pharmacy Services. Department: Fairview Home Infusion. Manual: Policy and Procedure Manual
Entity: Fairview Pharmacy Services Department: Fairview Home Infusion Manual: Policy and Procedure Manual Category: Home Infusion Subject: Midline (Extended Dwell Peripheral) Catheter Care and Management
More informationDr Alex Bradshaw Consultant Clinical Oncologist Sept 2016
Dr Alex Bradshaw Consultant Clinical Oncologist Sept 2016 Learning Points Recognising Acute Drug Reactions Preventing Acute Drug Reactions Treating Acute Drug Reactions Anaphylaxis Recognising Anaphylaxis
More informationSTANDARDIZED PROCEDURE REPROGRAMMING AND REFILLING INTRATHECAL BACLOFEN PUMPS and ACCESSING THE CATHETER ACCESS PORT (Adult,Peds)
I. Definition The purpose of this procedure is to allow the Advanced Health Practitioner (AHP) to reprogram and refill intrathecal Baclofen pumps, as well as access the catheter access port for those AHPs
More informationIV Link Staff. Infection Prevention & Control A Learning Package for IV Link Staff
IV Link Staff Infection Prevention & Control A Learning Package for IV Link Staff Purpose This learning package provides key infection prevention messages and direction for knowledge that you require as
More informationPeripherally Inserted Central Catheter (PICC) Booklet
Aintree University Hospital FT PICC Booklet: a real world example This local booklet is an example used in the NICE medical technology guidance adoption support resource for SecurAcath for securing percutaneous
More informationPHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight:
. (Patient Sticker) CDH 208-203 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name: Ordering Provider:
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationFundamentals of Flushing and Locking
Fundamentals of Flushing and Locking Vascular Access Devices Fundamentals of Flushing and Locking Purpose, Product, and Process 2016 BD. BD and the BD Logo are trademarks of Becton, Dickinson and Company.
More informationCentral Venous Access Devices. Stephanie Cunningham Amy Waters
Central Venous Access Devices Stephanie Cunningham Amy Waters 5 Must Know Facts About CVAD s 1) What are CVAD s? 2) What are CVAD s used for? 3) How are these devices put in? 4) What are the complications
More informationCurraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices
Curraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices Date re-approved: 27 th Jan 2015. Version No: 2 Revision Due: 2018 Index code: CLIN028 Disclaimer: The information
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationMary Lou Garey MSN EMT-P MedFlight of Ohio
Mary Lou Garey MSN EMT-P MedFlight of Ohio Function Prolonged and frequent access to venous circulation Allows for patient to carry on normal life; decrease number of needle sticks Medications, parenteral
More informationNeedle free connectors, port protectors and infection risk today. Giancarlo Scoppettuolo A. Gemelli University Hospital Foundation, Rome
Needle free connectors, port protectors and infection risk today Giancarlo Scoppettuolo A. Gemelli University Hospital Foundation, Rome 1 Pathogenesis of CRBSI and Prevention of extra and intraluminal
More information7/25/2016. Use of Epinephrine in the Community. Knowledge Amongst Paramedics. Knowledge Amongst Paramedics survey of 3479 paramedics
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures Speaker s bureau Genentech, Teva Consultant Genentech, Teva Outline Knowledge gap Definition Pathophysiology
More informationMANITOBA RENAL PROGRAM
MANITOBA RENAL PROGRAM SUBJECT Use of Closed Needleless Access Device with Hemodialysis Central Venous Catheters (CVC) SECTION CODE 30.20.04 30.20 Vascular Access AUTHORIZATION Professional Advisory Committee,
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationALIMTA Administration and Education Guide
ALIMTA Administration and Education Guide A comprehensive guide that includes customizable dosing handouts for patients and caregivers ALIMTA is indicated for the initial treatment of patients with locally
More informationNote: There are other bendamustine protocols, ensure this is the correct one for a given patient.
INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within
More informationOBJECTIVES PRINCIPLES AND PRACTICES OF ASEPSIS
Module E OBJECTIVES PRINCIPLES AND PRACTICES OF ASEPSIS Statewide Program for Infection Control and Epidemiology (SPCE) UNC School of Medicine Describe the principles and practice of asepsis Discuss the
More informationChapter 8. Learning Objectives. Learning Objectives 9/11/2012. Anaphylaxis. List symptoms of anaphylactic shock
Chapter 8 Anaphylaxis Learning Objectives List symptoms of anaphylactic shock Discuss role of immune system in fighting antigens Define allergic response Learning Objectives Describe body s response to
More informationLecture 10: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids. Vincristine (Oncovin):
Lecture 10: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids Vincristine (Oncovin): Uses: Acute leukemia, Hodgkin s lymphoma (part of the MOPP, COPP, BEACOPP regimens); non- Hodgkin
More informationYOUR GUIDE TO PATIENT SUPPORT SERVICES
YOUR GUIDE TO PATIENT SUPPORT SERVICES Please see Important Safety Information About ONIVYDE (irinotecan liposome injection) on pages 6 7. WHAT IS PROVYDE (ONIVYDE ACCESS SERVICES)? PROVYDE is a team of
More informationIV Fluids. Nursing B23. Objectives. Serum Osmolality
IV Fluids Nursing B23 Objectives Discuss the purpose of IV Discuss nursing interventions in IV therapy Identify complications of IV therapy Differentiate between peripheral line, central line, and PICC
More informationLUNG. Tumour Group: Regimen name / acronym. Place in therapy. Induction chemotherapy. Regimen name / acronym. Place in therapy
Tumour Group: LUNG Non-small cell lung cancer Adjuvant Vinorelbine PO* / Cisplatin 1 x x First line Vinorelbine IV / Cisplatin x First line Vinorelbine IV / Carboplatin x cisplatin Vinorelbine PO* / Cisplatin
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Yescarta) Reference Number: CP.PHAR.XX Effective Date: 10.31.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationIt s the solution that counts. 3M skin antiseptic products
It s the solution that counts 3M skin antiseptic products SoluPrepTM Brand The impact of surgical site infections Surgical site infections (SSIs) are a major burden on healthcare systems, providers and
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationUrinary Catheters. Prevalence of Infections
Urinary Catheterisation Urinary catheterisation is defined as an intervention to enable the emptying of the bladder by insertion of a catheter. Catheters can be short term less than 28 days or long term
More informationClinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationRITUXIMAB RHEUMATOLOGY VASCULITIS
. PHYSICIAN (Patient Sticker) ORDER SET : CDH 208-237 Approved - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name:
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationLecture 11: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids (we will discuss 3) Vincristine (Oncovin):
Lecture 11: Antimitotic agents cell cycle specific (M phase mainly) 1. Vinca alkaloids (we will discuss 3) Vincristine (Oncovin): Uses: Acute leukemia, Hodgkin s lymphoma (part of the MOPP, COPP, BEACOPP
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationVascular access in practice: best practice update
Vascular access in practice: best practice update Nicola York Clinical Nurse Manager Vascular Access Oxford University Hospitals NHS Foundation Trust June 2016 Objectives Patient assessment Best practice
More informationImmune System. Chapter 40
Immune System Chapter 40 Germ Theory of Disease Idea that microorganisms can cause infectious disease. Disease: any change that disrupts normal body function. What are the 5 main agents that cause disease?
More informationAllergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis
Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases
More information